Evidence map›Paper›PMID 26384391›Full record

ArticleDiabetes care2015

Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans.

You-Cheol Hwang, Tomoshige Hayashi, Wilfred Y Fujimoto, Steven E Kahn, Donna L Leonetti, Marguerite J McNeely, Edward J Boyko

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

You-Cheol HwangSeattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
Tomoshige HayashiDepartment of Preventive Medicine and Environmental Health, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Wilfred Y FujimotoDepartment of Medicine, University of Washington School of Medicine, Seattle, WA.
Steven E KahnDepartment of Medicine, University of Washington School of Medicine, Seattle, WA Hospital and Specialty Medicine Service, VA Puget Sound Health Care System, Seattle, WA.
Donna L LeonettiDepartment of Anthropology, University of Washington, Seattle, WA.
Marguerite J McNeelyDepartment of Medicine, University of Washington School of Medicine, Seattle, WA.
Edward J BoykoSeattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA Department of Medicine, University of Washington School of Medicine, Seattle, WA eboyko@uw.edu.
University of Washington · USVA Puget Sound Health Care System · USOsaka City University · JP

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
ZIPRASIDONE IN NORMAL HEPATIC FUNCTION SUBJECTS &IN HEPATIC DYSFUCTIN SUBJECTSM01RR000037 · NCRR · UNIVERSITY OF WASHINGTON · PI MCDONALD, RUTH C · 1985 to 2007
$33.8M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
NCRR NIH HHS M01 RR000037NCRR NIH HHS RR-00037NIDDK NIH HHS DK-17047NIDDK NIH HHS DK-35816NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816
6 · The paper itself

Abstract

objectiveRecent studies have suggested that HDL cholesterol is inversely associated with the development of type 2 diabetes. However, little is known about the association between different HDL subclasses and the risk for future type 2 diabetes. RESEARCH DESIGN AND

methodsThe study enrolled 406 Japanese Americans (51% male) without diabetes, aged 34-75 years. Oral glucose tolerance tests were performed to determine type 2 diabetes status at baseline, 2.5 years, 5 years, and 10 years after enrollment. HDL2, HDL3, total HDL cholesterol, and visceral adipose tissue (VAT) area by computed tomography were measured at baseline.

resultsIn univariate analysis, total HDL and HDL2 cholesterol were inversely associated with the incidence of type 2 diabetes, but HDL3 cholesterol was not. In multivariate analysis, total HDL cholesterol (odds ratio per 1-SD increment, 0.72 [95% CI 0.52-0.995], P = 0.047) and HDL2 cholesterol (odds ratio per 1-SD increment, 0.64 [95% CI 0.44-0.93], P = 0.018) were inversely associated with the risk for type 2 diabetes independent of age, sex, BMI, waist circumference, family history of diabetes, lifestyle factors, systolic blood pressure, lipid-lowering medication use, triglyceride level, HOMA-insulin resistance, and 2-h glucose; however, HDL3 cholesterol was not associated with diabetes risk. The association between diabetes risk and total HDL and HDL2 cholesterol became insignificant after adjustment for VAT area.

conclusionsSubjects with higher HDL2 cholesterol were at lower risk for incident type 2 diabetes, but this association was confounded by and not independent of VAT. Higher HDL3 cholesterol was not associated with diabetes risk.

Indexed as

AdultAgedAsianCholesterol, HDLDiabetes Mellitus, Type 2FemaleHumansIntra-Abdominal FatMaleMiddle AgedProspective StudiesRadiographyRisk FactorsCholesterol, HDL

Identifiers

PMID26384391
PMCPMC4613920
OpenAlexW2203861365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.